Deals channel feed – Endpoints News

Deals channel feed

Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline

5 years ago

The lead drug in Alexion’s $930M buyout deal last fall just flopped — adding injury to analysts’ M&A insults

5 years ago

Roche/Genentech doubles down on tau, fronting $120M cash to ally on a 2-pronged strategy to fight Alzheimer’s

5 years ago

AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’

5 years ago

Fast follow: EQRx engineers $410M-plus worth of deals to CDK4/6, EGFR drugs

5 years ago

Juno/WuXi's cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come

5 years ago

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

5 years ago

Gilead lines up a $1.55B biotech buyout deal as CEO Dan O’Day invests in his latest cancer blockbuster dream

5 years ago

Roche partners on a slate of Jnana's immunology, neurology targets, rewarding its faith in the SLC transporter class

5 years ago

BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech

5 years ago

GSK injects $293M cash into CureVac, forging a deal to develop new mRNA vaccines and antibodies

5 years ago

Suggested by Bloomberg, blessed by analysts, could an M&A match with a certain MS player be far off for blockbuster-hungry Sanofi?

5 years ago

Gilead's ex-R&D chief Bischofberger heads back to the biotech giant to pick up a pair of late-stage drugs that had been put aside

5 years ago

Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson

5 years ago

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint

5 years ago

Massachusetts biotech Revitope scores first collaboration thanks to dual-engaging T cell platform

5 years ago

Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey

5 years ago

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

5 years ago

Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing companies over the top

5 years ago

Merck expands scope of Zymeworks antibody alliance, adding close to $900M in milestones

5 years ago

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

5 years ago

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

5 years ago

John Reed brings NK cells into Sanofi's CD38 rivalry with J&J — and offers thumbs up for Kiadis' new focus

5 years ago

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

5 years ago

First page Previous page 88 89 909192 93 94 Next page Last page